arrow
E

Elizabeth O. Hexner

University of Pennsylvania
H指数:56
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Aberrant erythrocyte rigidity in JAK2 V617F myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage

JAK2 V617F骨髓增殖性肿瘤中异常红细胞刚性是并发血栓形成和出血的基础

2026-01-010
PRE
Performance of treatment response assessment at day 7 by baseline acute graft-vs-host disease severity

基于基线急性移植物抗宿主病严重程度的第7天治疗反应评估表现

2025-09-250
PRE
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHD

MAGIC复合应答:一种整合临床和生物标志物参数的急性GVHD新型终点指标

2025-08-190
OAAI
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer

胰腺癌中CAR T细胞耐药性的临床与分子解析

2025-08-180
OAAI
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

急性GVHD第28天治疗反应标准的修订:JSTCT与MAGIC的合作研究

2025-07-030
OAAI
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial

Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, et al. 静脉内双价CAR T细胞靶向EGFR和IL-13Rα2治疗复发性胶质母细胞瘤:一项1期临床试验。Nat Med. (2025). doi: 10.1038/s41591-025-03745-0

2025-06-010
PRE
Evolving racial/ethnic disparities in AML survival in the novel therapy era

新型疗法时代急性髓系白血病(AML)生存率的种族/族裔差异演变

2025-01-311
PRE
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

移植物抗宿主病治疗期间的系列临床和生物标志物监测确定了不同的风险阶层,包括超低风险组

2025-01-010
PRE
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

黑人和白人患者急性移植物抗宿主病 (GVHD) 严重程度及其结局的差异

2024-11-011
PRE
Cytokine-mediated CAR T therapy resistance in AML

细胞因子介导的AML car-t治疗耐药

2024-09-272
PRE
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
2024-06-282
OAAI
Amphiregulin, ST2, and REG3 α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
2024-06-140
OAAI
A Validated Risk Strati fi cation That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

包含神奇生物标志物的经过验证的风险分层可预测急性GVHD患儿的长期预后

2024-06-012
OAAI
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
2024-04-233
OAAI